DoxyPEP — Competitive Intelligence Brief

DoxyPEP (DoxyPEP) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Tetracycline antibiotic. Area: Infectious Disease / Sexual Health.

marketed Tetracycline antibiotic Bacterial 30S ribosomal subunit Infectious Disease / Sexual Health Small molecule

Target snapshot

DoxyPEP (DoxyPEP) — Chinese University of Hong Kong. DoxyPEP is doxycycline used as a post-exposure prophylaxis to prevent sexually transmitted infections by inhibiting bacterial protein synthesis.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
DoxyPEP TARGET	DoxyPEP	Chinese University of Hong Kong	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
tetracycline (BQ10)	tetracycline (BQ10)	National Taiwan University Hospital	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
hand mixed tobramycin	hand mixed tobramycin	Washington University School of Medicine	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Tobramycin Inhalant Product	Tobramycin Inhalant Product	Shanghai Pulmonary Hospital, Shanghai, China	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit
Minocycline (yes/no)	Minocycline (yes/no)	Medical University of South Carolina	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit
Amzeeq 4% Topical Foam	Amzeeq 4% Topical Foam	Edward Lain, MD	marketed	Tetracycline antibiotic	Bacterial 30S ribosomal subunit; matrix metalloproteinases
Gentamicin - three days	Gentamicin - three days	Murdoch Childrens Research Institute	marketed	Aminoglycoside antibiotic	Bacterial 30S ribosomal subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Tetracycline antibiotic class)

1. OraPharma · 2 drugs in this class
2. Vyne Therapeutics Inc. · 2 drugs in this class
3. Beijing Tiantan Hospital · 1 drug in this class
4. Clinica Universidad de Navarra, Universidad de Navarra · 1 drug in this class
5. Darier · 1 drug in this class
6. Edward Lain, MD · 1 drug in this class
7. Generic (originally Pfizer) · 1 drug in this class
8. Galderma R&D · 1 drug in this class
9. Johns Hopkins University · 1 drug in this class
10. Chinese University of Hong Kong · 1 drug in this class